Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | GC012F |
Trade Name | |
Synonyms | GC-012F|GC 012F |
Drug Descriptions |
GC012F are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets both B-cell maturation antigen (BCMA; TNFRSF17) and CD19, potentially leading to antitumor activity (J Clin Oncol 41, 2023 (suppl 16; abstr 8005). |
DrugClasses | CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | C175471 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
GC012F | GC012F | 0 | 1 |